Recent studies support the use of bortezomib-based therapies in light chain amyloidosis (AL). We performed a retrospective analysis of the safety, efficacy and long-term survival (median follow-up 3 years) after bortezomib-based treatment in 28 consecutive patients with de novo AL deemed ineligible at initial presentation. The first 14 patients received bortezomib and dexamethasone (VD), and the second 14 patients received cyclophosphamide, bortezomib and dexamethasone (CVD; CyBorD). Both regimens were well tolerated with no treatment-related mortality. The overall hematological response (HR) rate was 93% in both the groups. Median time to response was shorter in the CVD group (39 days vs 96 days in the VD group; P = 0.002). Hematological and organ responses induced with bortezomib-based therapy enabled 8 (33%) of initially transplant ineligible patients to undergo autologous hematopoietic stem cell transplantation (AHCT), including 4 patients with cardiac stage III or IV. Seven of the eight patients (88%) who underwent subsequent AHCT achieved sustained HR at a median of 33 months posttransplant. These data suggest that bortezomib-based induction followed by AHCT is a viable therapeutic strategy for transplant-ineligible AL. Larger, multicenter prospective trials are necessary to confirm our findings.
INTRODUCTION
Long-term prognosis of multisystem immunoglobulin light chain amyloidosis (AL) is poor, with a median survival as short as 6 months. 1 Treatment with chemotherapy suppresses clonal plasma cells and production of amyloidogenic light chains, leading to improved organ function and survival. 2 However, patients with multiple organ dysfunctions, including advanced cardiac, AL and those with poor performance status pose treatment challenges. 3 Standard practice guidelines recommend melphalan plus dexamethasone for transplant ineligible patients. 4, 5 Bortezomib, a proteasome inhibitor, has been shown to induce hematological and organ responses in patients with AL, including patients with cardiac involvement. 6, 7 Prior studies using bortezomib-based induction regimens demonstrated hematological response (HR) rates of 67-94% with a median time to HR ranging between 0.7 and 2.1 months. 6, [8] [9] [10] [11] Here we describe treatment tolerability, clinical response and reversal of autologous hematopoietic stem cell transplantation (AHCT) eligibility in a retrospective analysis of 28 patients with AL treated with cyclophosphamide, bortezomib and dexamethasone (CVD) or with VD. Our patient cohorts were followed for a median of 39 months, significantly longer than in previous reports (that is,12-21 months).
SUBJECTS AND METHODS Patients
Twenty-eight consecutive patients with AL were treated at the Medical College of Wisconsin from 2006 to 2012. Patients had newly diagnosed, biopsy-proven AL and were ineligible for upfront AHCT after a transplant consultation. Patient characteristics are summarized in Table 1 . Patients with overt myeloma were excluded. AL patients were considered transplant ineligible if Karnofsky Performance Score (KPS) was ⩽ 70%, ⩾ 3 organs were affected, age was 470 years or advanced cardiac involvement was evident (troponin T ⩾ 0.06 ng/mL or N-terminal probrain natriuretic peptide ⩾ 5000 ng/L, New York Heart Association functional class ⩾ III, serum creatinine ⩾ 2.0 mg/dL or significant effusions or hypotension (systolic ⩾ 90 mm Hg)). 4, 12 Treatment and outcome IV cyclophosphamide). This regimen was designed prior to the publication of guidelines for bortezomib-based induction in AL. 6 Patients received a median of 6 cycles of CVD or VD (range 2-15). The median time from diagnosis to the start of treatment was 30 days. All patients were evaluable for response. Patients with 410% plasma cells from diagnostic bone marrow biopsy who achieved at least a partial response after 6 cycles of therapy were offered ongoing bortezomib maintenance 1.3 mg/m 2 IV every 2 weeks until disease progression or until selected for AHCT. Patients who became transplant eligible after induction therapy underwent autologous progenitor cell harvest with plerixafor and granulocyte colony-stimulating factor mobilization using a standard approach described by Dhakal et al. 13 No adverse events occurred during mobilization. The primary outcome was HR. Additional measured outcomes were organ responses, toxicity, overall survival and PFS. Organ involvement, organ response and HR were defined by recent criteria.
RESULTS

Hematological response
Patient responses are summarized in Table 1 . Response, outcome and disease status are presented longitudinally in Figure 1 . Overall, a HR occurred in 26 (93%) patients, including CR in 10 (36%) patients. Response rates were similar in both CVD-and VDtreated patients (93%). The median time to a HR was 44 days from the start of therapy. Of note, the median time to HR was significantly shorter in the CVD group compared with the VD group (39 vs 96; P = 0.002, Wilcoxon rank-sum test). It should be noted that the median time to HR with VD was longer in this study compared with other published reports (3.2 vs 1.7-2.1 months) and may be secondary to the lower dose used in this study. 6, 9 Organ response Overall, 17 (61%) patients experienced at least one organ response (CVD, 8/14 (57%); VD, 9/14 (64%)). Responses occurred in the kidneys (4 CVD; 2 VD), heart (7 CVD; 4 VD) and liver (2 CVD; 1 VD). Within the CVD cohort, four patients with cardiac stage III and two with cardiac stage IV experienced a cardiac response. Three patients with cardiac stage III receiving VD demonstrated a cardiac response. One patient with severe renal involvement demonstrated improvement after 1 month of VD and no longer required dialysis.
Reversal of AHCT eligibility All patients were transplant ineligible at diagnosis either due to age (n = 4), organ function or KPS. Improvement of organ function (cardiac, n = 6; renal, n = 2) and KPS after induction enabled 8 patients (5 CVD and 3 VD) to receive delayed AHCT. Two CVD and three VD patients qualified after six cycles of therapy, while three CVD patients received maintenance bortezomib prior to AHCT. Although only 8 AHCT were performed, hematopoietic progenitor cells were successfully harvested from 12 patients (CVD, n = 7; VD, n = 5) In the CVD group, two patients with cardiac stage III, one patient with cardiac stage IV and two patients with renal involvement improved with treatment and became transplant eligible. Three patients had achieved CR while PR or VGPR was observed in the remaining two patients prior to AHCT. All five patients were in sustained HR with no relapses at a median of 33 (23-40) months after AHCT. In the VD group, one patient with cardiac stage III, one patient with renal involvement and one patient with multi-system organ improvement became transplant eligible. One patient achieved VGPR prior to AHCT and has maintained CR 6 years post-AHCT without any additional treatment. One patient, who achieved CR prior to AHCT, died from transplant-related complications resulting in septic shock and subsequent multi-organ failure. The third patient achieved PR prior to AHCT but progressed 3 months post transplant and died from AL complications.
Progression and survival
The median follow-up from the start of treatment for the entire cohort was 39 months (CVD, 33.3 (17-40); VD, 48.4 (24-77)). The median overall survival had not been reached at the time of analysis for those who received CVD. The VD group had a median overall survival of 34.4 months (6.6%-NA; Kaplan-Meier estimator). The median PFS for the CVD and VD cohorts were 28.8 and 24.5 months, respectively. The 3-year survival probability was 64% (44-95%) in the CVD group and 50% (23-72%) in patients treated with VD.
Treatment-related toxicities There was no mortality attributable to treatment in either group during induction. Two grade 3 peripheral neuropathy toxicities were observed. Neuropathic symptoms were exacerbated by treatment in two of the six patients who had prior peripheral neuropathy, and one patient required discontinuation of treatment. Six (21%) patients experienced gastrointestinal complications, including ileus, nausea and diarrhea. Two patients in the CVD group who developed ileus tolerated additional standard dose CVD after symptoms resolved. Hematological toxicity was negligible, with no patients requiring blood or platelet transfusions. Mild non-febrile neutropenia (ANC 1000-1500 cell/mm 3 ) occurred in 4 (14%) patients; however, this was self-limiting and did not require dose reduction.
Deaths Thirteen (46%) of the 28 patients (VD, 8 (57%); CVD, 5 (36%)) died. Of those treated with VD, one patient had no HR and died from complications related to AL. Two patients achieved a complete HR but died either from complications secondary to AHCT (sepsis) or from causes unrelated to AL or AHCT. Four patients achieved a PR but relapsed and died from progressive disease. One patient who had a PR died of causes unrelated to AL or AHCT. In the CVD group, one patient had no HR and died from AL. Two patients achieved hematological PR but died from AL-related cardiac disease. One patient achieved a PR and continued to receive maintenance therapy but relapsed 12 months later and died from progressive AL. One patient achieved a CR and maintained HR for 2 years prior to relapse and death from AL.
DISCUSSION
The goal of treatment strategies in AL is to rapidly achieve hematological and organ responses to prevent further end-organ damage. This study suggests that long-term survival and sustained CR are possible for AHCT ineligible patients with multi-system and advanced cardiac AL. We suggest that bortezomib-based induction promoted organ improvement and successful AHCT in previously ineligible patients. We propose that rapid HR was essential for efficient hematopoietic progenitor cell harvest, organ and KPS improvement and successful, low-risk AHCT. Remarkably, only one patient who underwent AHCT had progressed at a median follow-up of 39 months after AHCT. The decision to proceed with AHCT in patients with AL is best addressed in the setting of a randomized controlled trial. Although only six out of the seven patients achieved PR or CR after AHCT, three of these patients had a CR prior to transplant. In addition, two patients receiving CVD and three patients receiving VD achieved long-term remissions without use of AHCT. Thus the impact of AHCT compared with chemotherapy alone remains unknown. The potential benefits of AHCT should be weighed against risks. In this study, one patient experienced treatmentrelated mortality (12.5%) from sepsis. Candidates for AHCT should be chosen judiciously, and AHCT should be performed at highvolume transplant centers with multidisciplinary AL programs.
